ABC of Mens Health Blog

Men’s Health News
New Zealand’s Director-General of Health, Stephen McKernan, is warning people about the potential health dangers associated with three products promoted and sold in New Zealand for sexual enhancement or the treatment of erectile dysfunction which may contain an undeclared therapeutic substance.
buy generic cialis This statement about the three products is being issued by the Director-General under Section 98 of the Medicines Act 1981, following investigations by the Ministry of Health’s medicines safety arm, Medsafe.
The products are Rize 2 the Occasion (also known as Rize 2), Rose 4 Her and Viapro. The products appear to have been sold by retail from ‘adult’ shops and over the internet.
The United States FDA has issued a warning that products on the US market with these names had been tested and recalled after they were found to contain the substance thiomethisosildenafil which is an analogue of sildenafil. Thiomethisosildenafil is expected to have similar therapeutic actions and adverse effects as sildenafil the active ingredient of the prescription medicine Viagra. Sildenafil is known to interfere with some heart medications and its use could be fatal to some individuals.
"Consumers should immediately stop taking Rize 2 the Occasion, Rose 4 Her and Viapro and seek medical advice from their doctor if they are taking other medicines or if they have felt unwell when taking any of these products," said Mr McKernan.
Stephen McKernan also warned that Medsafe has previously identified a number of other products being sold in shops and over the internet to treat erectile dysfunction or for sexual enhancement that have also been adulterated with prescription medicines. Consumers should treat erectile dysfunction products offered for sale without a prescription with caution and seek medical advice before using them.
Under the medicines legislation, sponsors, distributors and importers are responsible for the products they sell and must be aware of all the active ingredients they contain and seek approval prior to selling them if required by the legislation.

comprare il cialis senza ricetta | generique kamagra en ligne acheter | Generico kamagra pillole senza ricetta

UroToday.com - While erectile dysfunction has been described since ancient times, adequate treatment has only been available for the last three decades. Modern penile prosthetic devices were first developed in the early 1970s when Small et al. along with Scott et al. reported the implantation of penile prosthetic devices into the corpora cavernosa to fill the corpora cavernosa and provide a physiologically functional erection with good cosmetic results.
Semirigid rod and mechanical prostheses available today are the successors of the devices designed in the 1970s. These devices, while easier to implant, have few advantages over the newer inflatable devices because infection and mechanical malfunction rates are similar. The semirigid devices consist of a central metal core and a silicone elastomer rod while the mechanical Dura II implant is a series of disks held in position by a central cable. The latter design facilitates positioning of the implant between uses.
The three-piece inflatable penile prostheses vary in construction from three-layer silicon/Dacron/Lycra to a single layer of silicon or Bioflex . Options include girth expansion and/or length elongation. Design modifications over the past two decades have decreased mechanical malfunction rates from greater than 30% to less than 5% and antibiotic coating has reduced the infection rates from over 4% to fewer than 1%.
The three-piece inflatable penile prostheses continue to be the most satisfactory prostheses. These prosthetic devices produce the most natural appearing erection in girth, length, and with satisfactory rigidity and excellent flaccidity for optimal concealment. They also have advantages for many patients with complex penile implantations because the flaccid position removes pressure from the corporal cavernosa and decreases the possibility of erosion in these highly difficult implantations.
Patients chosen for penile implantation therapy are usually those that have failed PDE5 inhibitors and less invasive therapy. Careful informed consent is critical in counselling patients before surgery. Post operatively patients should be counselled to cycle their devices daily and that satisfaction increases over 3 to 6 months after implantation. Kaufen generishe viagra Multicenter studies have documented the long term satisfaction and normal mechanical function of penile implants and their satisfaction rates. Patients queried 5 years after surgery were using their implants an average of three times monthly.
Presented by: Culley C. Carson, MD, at the Masters in Urology Meeting - July 31, 2008 - August 2, 2008, Elbow Beach Resort, Bermuda
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to:
www.urotoday.com
Copyright © 2008 - UroToday
kaufen cialis Ohne Rezept | Kaufen generishe viagra | generishe cialis soft pillen Ohne Rezept

UroToday.com Peyronie’s disease is a scarring phenomenon affecting the tunica albuginea of the penis. Scar tissue forms "plaques" that can result in pain with erection, penile deviation, penile shortening, indentation, and/or erectile dysfunction. Buy generic ultram It is associated with difficulty with sexual intercourse and as such it is associated with loss of self-esteem and depression on the part of the patient and often on the part of the patient’s partner. There are no approved medical therapies for the treatment of Peyronie’s disease. Surgical treatment of Peyronie’s disease must be highly individualized, and various surgeons all have their "best way" of dealing with the problem.
Peyronie’s disease was described by Francois de la Peyronie in 1743. Fallopius in 1561 probably described the entity that bares Peyronie’s name. Peyronie’s disease is incurable, patients require reassurance, they may benefit from medical therapy, and fortunately few require surgery. As mentioned, the scar tissue impedes the expansion of the corpora cavernosa.
Peyronie’s disease has been associated with some medications. Beta blockers have been implicated, however, subsequent studies have not verified that relationship, and if there is a relationship to beta blockers, it is probably via erectile dysfunction, and not cause and effect of the beta blocker itself. The association with phenytoin has never been founded and is probably not real. A very nice study by Lyles from the University of North Carolina has associated Peyronie’s disease with patients who have Padgett’s disease of the bone. Diabetes mellitus has been implicated, and it is probably again via erectile dysfunction. About 40% of patients with Peyronie’s disease will show evidence of Dupuytren’s disease, albeit many will be non-contractile. A lesser percentage will show evidence of Ledderhose’s disease, and a very small number will have tympanosclerosis.
Peyronie’s disease is a disease of patients between 45 and 65 years with a mean onset of 53 years old. The asymptomatic prevalence has been estimated to be as high as 20-25%. The years of peak incidence of Peyronie’s disease as it turns out are also the years during which the body begins to age, tissues lose elasticity, and men note the onset of erectile dysfunction.
The current theory with regards to the etiology of Peyronie’s disease involves trauma to the insertion of the septal fibers. The dorsum appears to be particularly vulnerable. To this date, there is no firm association to HLA subtypes, autoimmune disease, but Peyronie’s disease is certainly a disease of hyperactive wound healing.
The scar tissue is composed of dense collagen with decreased elastin. Patients can demonstrate dystrophic calcification and in some cases cartilaginous metaplasia. TGF??1 has been implicated as a part of the process involving the etiology of Peyronie’s disease. Other gross factors are also expressed, those being platelet derived growth factors A and B. TGFb1 has been implicated with other soft tissue fibrosis. It is implicated in ED. TGF??1 increases the synthesis of fibroblasts; and in short, it causes increased connective tissue as it governs the scarring process. It inhibits collagenase, and because of the unique anatomy of the insertion of the septal fibers, may be involved in a process of self-induction. All agree that Peyronie’s disease is a disease of two phases, an active or immature phase and a mature or quiescent phase. What the practitioner does for Peyronie’s disease is in many cases phase specific.
The physician seeing a patient with Peyronie’s disease cannot underestimate the psychological impact on the patient and on his partner. With regards to medical management, the place of vitamin E, potaba, Colchicine, Tamoxifen, Carnitine, Pentoxifylline, and PDE5 inhibitors will be discussed. Where there are pertinent randomized controlled trials, those will be reviewed. It is clear that rigorous well-designed controlled studies have in the past not been uniformly done. They are needed, and we are in an era where that deficiency is being addressed. Intralesional injection will be addressed as will the randomized controlled trials associated with that. The place of topical therapy will be addressed, along with innovative delivery mechanisms such as iontophersis and electromotive therapy. The literature will be reviewed with regards to lithotripsy, and the place of combined medical therapy likewise reviewed.
A patient becomes a surgical candidate when he has stable and quiescent disease and that usually is a time that is greater than a year from onset of symptoms. The deformity should be stable for at least 3-6 months. The patient should be erectile pain free. These patients require detailed assessment of their erectile function, and it is imperative that a true informed consent be conducted with the patient. Surgical management options include the plication or corporoplasty techniques. I will review my techniques for these procedures. The place of excision or incision with grafting will be demonstrated and reviewed and the place of prosthetic placement likewise will be reviewed. As mentioned, surgery for Peyronie’s disease must be highly individualized, and in most cases, lecturers focus on those procedures that they have had the best success with.
Presented by: Gerald H. Jordan, MD, FACS, FAAP, at the Masters in Urology Meeting - July 31, 2008 - August 2, 2008, Elbow Beach Resort, Bermuda
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to:
www.urotoday.com
Copyright © 2008 - UroToday
View drug information on Pentoxifylline.
Generic diflucan pills no prescription | generic zithromax online buy | Generic viagra pills no prescription

An innovative study appearing in the August issue of The Journal of Sexual Medicine examined, for the first time, if noseless bicycle saddles would be an effective intervention for alleviating deleterious health effects, erectile dysfunction and groin numbness, caused by bicycling on the traditional saddle with a protruding nose extension. kaufen kamagra Ohne Rezept Results from this study may be useful for the estimated 5 million recreational cyclists to alleviate perineal discomfort and maintain sexual health.
Ninety bicycling police officers from 5 metropolitan regions in the U.S. (Northwest, Southern, Desert West, Midwest, and Southeast) using traditional saddles were evaluated prior to changing saddles and then again after 6 months of using the noseless bicycle saddle.
The findings show that use of the noseless saddle resulted in a reduction in saddle contact pressure in the perineal region. There was a significant improvement in penile tactile sensation, and the number of men indicating they had not experienced genital numbness while cycling for the preceding 6 months rose from 27 percent to 82 percent using no-nose saddles. Use of the noseless saddle also resulted in significant increases in erectile function as assessed by the initial evaluation, but there were no significant changes noted in Rigiscan® measures, a method used to record penile rigidity while the subject sleeps. With few exceptions, bicycle police officers were able to effectively use no-nose saddles in their police work and 97 percent of officers completing the study continued to use the no-nose saddle afterward.
Dr. Steven Schrader of the National Institute for Occupational Safety and Health in Cincinnati, first author of the study and the recent co-recipient along with his research team of a Bullard-Sherwood Research-to-Practice Award in the Interventions Category for "Health Effects of Occupational Cycling" stated, "No-nose saddles are a useful intervention for bicycling police officers alleviating pressure to the groin and improving penis health. Different saddle designs may require some re-learning of ‘how to ride a bicycle,’ but the health benefits to having unrestricted vascular flow to and from the penis and less penile numbness is self-evident."
Dr. Irwin Goldstein, Director, Sexual Medicine, Alvarado Hospital, San Diego C.A., and editor-in-chief of The Journal of Sexual Medicine, wrote an accompanying editorial entitled "The A, B, C’s of The Journal of Sexual Medicine: Awareness, Bicycle Seats, and Choices".
"For the first time, we have a prospective study of healthy policemen riding bikes on the job, using wider, no-nose bike saddles for 6 months. Not only did their sensation improve, their erectile function also improved. Changing saddles changed physiology. This is a landmark study for our field that that is important for future riders, and modification of lifestyle showing improvement without any active treatment."
"Cutting Off the Nose to Save the Penis."
Steven M. Schrader, Michael J. Breitenstein, Brian D. Lowe.
The Journal of Sexual Medicine
DOI: 10.1111/j.1743-6109.2008.00867.x Volume 5 Issue 8 (August 2008).
To view the abstract for this article, please click here.
The Journal of Sexual Medicine was founded in 2004 and is the official journal of the International Society for Sexual Medicine, its five regional affiliated societies and the International Society for the Study of Women’s Sexual Health. It publishes multi-disciplinary basic science and clinical research to define and understand the scientific basis of male and female sexual function and dysfunction.
The Journal of Sexual Medicine
generishe cialis online kaufen mastercard | Buy levitra pills mastercard | Kaufen generishe cialis

Men’s Health News
acheter generic kamagra For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The NIDDK Prostate Research Strategic Plan is the culmination of discussions and meetings among experts over the past two years in an effort to outline a strategic vision for research into these elusive and multi-faceted diseases.
"The NIDDK Prostate Research Strategic Plan reflects NIH?s commitment to advancing translational research by facilitating planning efforts among basic scientists, clinicians, advocacy groups, and patients," said NIDDK Director Griffin P. Rodgers, M.D. "The educational summaries in each section of the plan provide clear explanations of the scientific data and the reasoning behind each of the recommended research priorities."
The research area of benign prostate disease includes two of the most significant non-cancerous disorders affecting males - benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). BPH, an enlargement of the prostate gland, is often associated with lower urinary tract symptoms (LUTS). LUTS, which can include symptoms such as overactive bladder, restricted or excessive urination, and sensations of urgency, affects men of all races and ethnic groups and can become severe over time. An estimated 50 percent of men in their 50s have BPH and 26 to 46 percent of men between the ages of 40 and 79 have moderate to severe symptoms. CP/CPPS is generally described as inflammation of the prostate gland. There is no detectable bacterial basis, but CP/CPPS sometimes is associated with urinary symptoms, pain, and sexual dysfunction. The source of the pain in this syndrome is unknown and there are no generally effective methods for preventing or treating the condition.
The NIDDK Prostate Research Strategic Plan addresses the four major research areas judged critical for advancing the field. These include basic science, epidemiology and population-based studies, translational research, and clinical sciences. Recommendations from the plan include:
Promote interdisciplinary research that focuses on how benign prostate diseases are influenced by other organ-specific diseases and systemic conditions, such as obesity, high blood pressure, high cholesterol, cardiovascular disease, diabetes, and erectile dysfunction. For example, the possible influence of high blood pressure on BPH/LUTS is a previously unexplored area of research.
Study the primary prevention of benign prostate diseases, including possible benefits of lifestyle changes such as avoidance of alcohol and caffeine, frequency of sexual practice, pelvic massage therapy, stress reduction, and diet modulation for relief of CP/CPPS.
Develop data and human tissue resources from patients of various ages to derive information useful in investigating risk factors, underlying causes and natural history of disease progression, quality of life, quality of care, and decision making regarding treatment of benign prostate disease. Develop imaging approaches and other biomarker studies to assess severity and risk of progression based on physical and cellular findings.
Develop targeted medical therapies based on new insights into disease-relevant cellular pathways and physiological events.
Develop standardized, clinically significant benign prostate disease syndrome definitions and classifications based on measurable phenotypic features.
Train and mentor epidemiologists, health services researchers, clinical investigators, and students interested in the study of benign prostate disease.
"The long-standing, unanswered questions about the causes of these disorders prompted the NIDDK to examine the state of the science and to develop a new vision for future research," explained Chris Mullins, Ph.D., NIDDK?s director of basic cell biology programs in urologic and kidney disease. "As part of this process we convened the Prostate Research Planning Committee, composed of clinical and basic scientists and epidemiologists from around the country, to review and evaluate past and current research and to make individual recommendations for new research priorities. The NIDDK Prostate Research Strategic Plan is the result of that collaborative effort."
The plan is designed to be read by a broad audience of researchers, clinicians, advocacy groups, representatives of funding organizations, and patients. Each major section includes a mission statement, a lay summary, an overview of current knowledge, and high-priority recommendations for future research. The plan is online at and can be purchased online in print or compact disc format at http://catalog.niddk.nih.gov/PubType.cfm?Type=182&CH=NKUDIC.
NIDDK conducts and supports research in diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic, and hematologic diseases. Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe, and disabling conditions affecting Americans.

Kaufen viagra pillen mastercard | generic cialis online buy mastercard | Comprar levitra sin receta